Fusion of an EGFR-antagonistic affibody enhances the anti-tumor effect of TRAIL to EGFR positive tumors

已完结 10 由诗奕发布于 2025/1/14 16:42:30

DOI:10.1016/j.ijpharm.2022.121746
作者：Dianlong Jia ,?Feifei Wang ,?Yue Lu ,?Ping Hu ,?Rui Wang ,?Guangyong Li ,?Renmin Liu ,?Jun Li ,?Huimin Liu ,?Qing Fan ,?Fengjiao Yuan
文献类型：期刊论文
补充材料：只需要正文

Elsevier

Abstract：Tumor necrosis factor-related apoptosis ligand (TRAIL) is a promising antitumor agent candidate for its selective proapoptotic activity to various tumor cells. However, TRAIL showed limited

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:Royal Society of Chemistry (RSC)用于CO2还原的膜电极组件电解槽的进展和挑战